Program
ianalumab
Also written as “VAY736”, “Ianalumab” and “ianalumab s.c. q4w”.
In Novartis’s pipeline, BAFF-R inhibitor, ADCC-mediated B-cell depletor
. Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Lupus Erythematosus, Systemic · Sjogren's Syndrome · Lupus Nephritis · Arthritis, Rheumatoid, led by Novartis.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 3416 open or running | phase 3since Jul 12, 2017 | Aug 23, 2013 | Mar 26, 2027phase 3 · NCT05639114 |
- Named in Novartis’s own pipeline as
VAY736 (ianalumab)
, phase 4, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 18 earlier studies, Aug 23, 2013 to Apr 7, 2022.
- Jun 9, 2017Named ianalumabINNProposed as its International Nonproprietary Name in WHO's List 117 · before, VAY736
- Nov 4, 20225 phase 3 studiesNCT05639114, NCT05624749, NCT05653349 and 2 more
- May 15, 2023Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT05885555 · 41 enrolled · United States, Argentina, Australia and more
- Aug 3, 2023Phase 3 study in Sjogren's SyndromeNCT05985915 · 612 enrolled · United States, Argentina, Australia and more
- Oct 2, 2023Phase 3 study in Lupus Erythematosus, SystemicNCT06133972 · 550 planned · United States, Argentina, Australia and more
- Feb 28, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06293365 · 155 enrolled · United States, Argentina, Canada and more
- May 8, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06411639
- Jun 17, 2024Phase 2 study in Scleroderma, DiffuseNCT06470048 · 203 enrolled · United States, Argentina, Austria and more
- Nov 11, 2024Phase 3 study in Lupus NephritisNCT06711887 · 348 planned · United States, Brazil, China and more
- May 5, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07039422
- Feb 12, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07421167 · 164 planned · United States
- May 26, 2026Phase 3 study in FatigueNCT07621809 · 570 planned · United States, Australia, Austria and more
- Jun 15, 2026Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT07660172 · 36 planned
- Oct 1, 2026Primary completion moved from 2030-04-08 to 2034-04-03Date moved laterphase 3 · +48 months · NCT06133972
- Oct 15, 2026Phase 2 study withdrawnStudy stoppedNCT07039422 · “The study was discontinued due to evolving scientific \& feasibility considerations that could adversely affect recruitment, thereby redu…”
Ahead
- Mar 26, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05639114
- Apr 12, 2027Primary completion: phase 3 study in Lupus Erythematosus, SystemicNCT05624749
- Jul 30, 2027Primary completion: phase 2 study in Scleroderma, DiffuseNCT06470048
- Sep 21, 2027Primary completion: phase 3 study in Lupus NephritisNCT05126277
TargetBeta
“BAFF-R inhibitor, ADCC-mediated B-cell depletor”the company's pipeline, read by Claude · source
“A fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 13C binding agent”ChEMBL 37, by rule
Other programs on TNFRSF13C
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-BAFFR Monoclonal Antibody ESG206rule | shanghai-escugen-biotechnology-co-ltd | phase 2 | 5 |
| Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199rule | Eli Lilly | phase 1 | 1 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660172Purpura, Thrombocytopenic, Idiopathic | 2 | Not yet recruiting | Apr 22, 2033 | 36 |
| NCT07621809Fatigue · United States, Australia, Austria and more | 3 | Recruiting | Aug 15, 2029 | 570 |
| NCT07421167Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Recruiting | Jan 18, 2029 | 164 |
| NCT07039422Purpura, Thrombocytopenic, Idiopathic | 2 | Withdrawn | Aug 30, 2030 | 0 |
| NCT06711887Lupus Nephritis · United States, Brazil, China and more | 3 | Recruiting | Aug 1, 2035 | 348 |
| NCT06470048Scleroderma, Diffuse · United States, Argentina, Austria and more | 2 | Active, not recruiting | Jul 30, 2027 | 203 |
| NCT06411639Lupus Erythematosus, Systemic | 1 | Withdrawn | Dec 17, 2025 | 0 |
| NCT06293365Lupus Erythematosus, Systemic · United States, Argentina, Canada and more | 2 | Active, not recruiting | Feb 17, 2026 | 155 |
| NCT06133972Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Recruiting | Apr 3, 2034 | 550 |
| NCT05985915Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 22, 2033 | 612 |
| NCT05885555Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 5, 2025 | 41 |
| NCT05653349Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 29, 2026 | 226 |
| NCT05653219Purpura, Thrombocytopenic, Idiopathic · United States, Argentina, Austria and more | 3 | Active, not recruiting | Jun 19, 2025 | 152 |
| NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA) · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 20, 2026 | 90 |
| NCT05624749Lupus Erythematosus, Systemic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 12, 2027 | 288 |
| NCT05639114Lupus Erythematosus, Systemic · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 26, 2027 | 436 |
| NCT05349214Sjogren's Syndrome · United States, Argentina, Australia and more | 3 | Active, not recruiting | May 13, 2025 | 506 |
| NCT05350072Sjogren's Syndrome · United States, Austria, Belgium and more | 3 | Completed | May 7, 2025 | 275 |
| NCT05124925Sjogren's Syndrome · France | 2 | Completed | Jun 26, 2024 | 21 |
| NCT05126277Lupus Nephritis · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Sep 21, 2027 | 452 |
| NCT04903197Lymphoma, Non-Hodgkin · Australia, China, Germany and more | 1 | Terminated | Feb 24, 2025 | 18 |
| NCT03827798Hidradenitis Suppurativa · United States, Austria, Belgium and more | 2 | Completed | Dec 4, 2024 | 248 |
| NCT03656562Lupus Erythematosus, Systemic · Argentina, Australia, China and more | 2 | Completed | Jul 27, 2022 | 107 |
| NCT03574545Arthritis, Rheumatoid · Germany, Jordan | 1 | Completed | Jul 18, 2024 | 48 |
| NCT03400176Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Terminated | Sep 29, 2023 | 39 |
| NCT03287414Idiopathic Pulmonary Fibrosis · United States, Canada, Germany and more | 2 | Terminated | Nov 25, 2020 | 30 |
| NCT03217422Hepatitis, Autoimmune · United States, Argentina, Belgium and more | 3 | Completed | Dec 28, 2023 | 68 |
| NCT02962895Primary Sjogren Syndrome · United States, Argentina, Austria and more | 2 | Completed | Jun 30, 2020 | 190 |
| NCT02675803Arthritis, Rheumatoid · Germany | 1 | Completed | Jan 22, 2018 | 65 |
| NCT02495129Sjogren's Syndrome | 2 | Withdrawn | Sep 2017 | 0 |
| NCT02137889Recurrence · United States, Spain | 1 | Terminated | Nov 2012 | 3 |
| NCT02038049Multiple Sclerosis · United States, Czechia, Ukraine | 2 | Terminated | May 5, 2015 | 8 |
| NCT02149420Primary Sjögren's Syndrome · Germany | 2 | Completed | Feb 7, 2018 | 27 |
| NCT01930175Pemphigus · United States, Austria, Bulgaria and more | 2 | Terminated | Sep 25, 2019 | 13 |
How it is read
Names in the registry
- “VAY736”, 15 entries
- “Ianalumab”, 11 entries
- “ianalumab”, 4 entries
- “ianalumab s.c. q4w”, 1 entry
- “ianalumab s.c. q12w”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Lupus Erythematosus, Systemic, 6 studies
- Sjogren's Syndrome, 6 studies
- Lupus Nephritis, 2 studies
- Arthritis, Rheumatoid, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.